CoChat

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

Open access
Davar, Diwakar, Zarour, Hassane M. · 2022 · Clinical Cancer Research

The DOI matches its Crossref record; 148 of the 151 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) proteins transformed the management of advanced cancers. Many tumor-intrinsic factors modulate immunological and clinical responses to such therapies, but ample evidence also implicates the gut microbiome in responses. The gut microbiome, comprising the bacteria, archaea, fungi, and viruses that live in the human digestive tract, is an established determinant of host immunity, but its impact on response to ICI therapy in mice and humans with cancer has only recently been appreciated. Therapeutic interventions to optimize microbiota composition to improve immunotherapy outcomes show promise in mice and humans with cancer. In this review, we discuss the rationale for gut microbiome–based cancer therapies, the results from early-phase clinical trials, and possible future developments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-21-1129

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Mechanisms for the effects of bacteria or bacterial metabolites on antitumor immune responses. MDSC, myeloid-derived suppressor cell; TME, tumor microenvironment.
Figure 1. Mechanisms for the effects of bacteria or bacterial metabolites on antitumor immune responses. MDSC, myeloid-derived suppressor cell; TME, tumor microenvironment.CC BY-NC-ND · PubMed Central
Figure 2. Spectrum of microbiome-specific interventions for the treatment of cancer.
Figure 2. Spectrum of microbiome-specific interventions for the treatment of cancer.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 148 references

Cited by

See all 40

Metadata

Authors
Davar, D., & Zarour, H. M.
Affiliations
University of Pittsburgh (US)
Corresponding author
Davar, Diwakar
Venue
Clinical Cancer Research
Published
2022-06-24
Volume
28
Issue
20
Pages
4370-4384
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4283464614
Cited by
40
References
151
Citations by year
2026: 5 · 2025: 15 · 2024: 5 · 2023: 12 · 2022: 3
FWCI
1.07
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (R01CA222203, R01CA257265, P50CA257265)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords
gut microbiota, cancer immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1, microbiota-based therapy, immunotherapy response, clinical trials, host immunity
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Humans, Immunotherapy, Neoplasms, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-1129
The paper
Davar, D., & Zarour, H. M. (2022). Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-1129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.